Who is eligible for clinical trial NCT06710756?

Participants must meet protocol criteria for Pancreatic Ductal Adenocarcinoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06710756 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-02

Lead-212 PSV359 Therapy for Patients With Solid Tumors (NCT06710756)

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Perspective Therapeutics

🩺 Plain-English Summary (8th-Grade Level)

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (14 items).

Location: University of Miami — Miami, Florida

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Aged ≥ 18 years
Satisfactory organ function as determined by laboratory testing
Eastern Cooperative Oncology Group performance (ECOG) status of 0 to 1
Life expectancy \> 3 months
Progressive disease despite standard therapy or for whom no standard therapy exists
Positive \[203Pb\]Pb-PSV359 SPECT/CT scan showing uptake of \[203Pb\]Pb-PSV359 in at least 1 known lesion on the 1-hour SPECT/ CT scan
Histological, pathological, and/or cytological confirmation of solid tumor malignancy that is locally advanced or metastatic

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Known hypersensitivity to the active agent or any of the excipients
Active secondary malignancy
Pregnancy or breastfeeding a child
Known brain metastases
Known active or uncontrolled infections requiring ongoing antifungals or antibiotics in the 3 days prior to enrollment
Known medical condition which would make this protocol unreasonably hazardous for the patient
Existence of any medical or social issues likely to interfere with study conductor that may cause increased risk to the subject or to others, e.g., lack of ability to follow radiation safety precautions
Medical history of a condition resulting in a severe allergic reaction such as anaphylaxis or angioedema to known components of the investigational product or excipients
Major surgery within 21 days prior to the administration of \[212Pb\]Pb-PSV359; the subject must be sufficiently recovered and stable before treatment administration
Diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to enrollment into the study
Current abuse of alcohol or illicit drugs

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (11 Sites)

University of Miami — Miami, Florida
Biogenix — Miami, Florida
University of Kansas — Kansas City, Kansas
University of Kentucky — Lexington, Kentucky
Mayo Clinic in Rochester, Minnesota — Rochester, Minnesota
Saint Louis University — St Louis, Missouri
Nebraska Cancer Specialists — Omaha, Nebraska
Ohio State University — Columbus, Ohio
University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
MD Anderson Cancer Center — Houston, Texas
University of Wisconsin — Madison, Wisconsin

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗